Skip to main content

Table 3 Recombinant proteins produced in BEV for the development of COVID-19’s recombinant anti-bodies and therapeutic proteins

From: Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

Proteins Modifications Host Cells Purification Method Specific Applications References
Spike protein, S2, receptor binding domain, antibodies, and fusion proteins Leader sequences, peptide tags signal peptide and restriction sites added. High Five/silkworm larvae Gel filtration and affinity chromatography Surface plasmon resonance (SPR), ELISA [87, 91, 92, 94,95,96]
Spike protein and antibodies Signal peptides, pre-fusion stabi-lized ectodomain, T4 fibritin tri-merization signal, peptide tags, linker, cleavage site, linker, transmembrane and tail domain added. Mutations introduced to the sequences. Codon optimization. High Five/ExpiSf9/silkworm larvae Affinity chromatography scFv, Fab, IgY and IgG antibody productions [94, 95, 97, 98]
Spike protein and receptor binding domain Signal peptide and peptide tag added. Biotinylation. Sf9/High Five Gel filtration, affinity, and size exclusion chromatography Protein crystallizations [85, 86, 89, 90, 93]
Receptor binding domain and angiotensin converting enzyme 2 Peptide tag added. Sf9/High Five Affinity chromatography Cell sorting [88, 99]
Spike protein and receptor binding domain Biotinylation Not mentioned Not mentioned B cell enrichment [91]
Spike protein and receptor binding domain Signal peptide and peptide tag added. Sf9/High Five Affinity and size exclusion chromatography Binding assays [93]